Bio­haven grabs TYK2/JAK1 drug for $20M to start, $950M on the line — to go af­ter Parkin­son's

Bio­haven is bet­ting big on tar­get­ing brain dis­or­ders such as Parkin­son’s and po­ten­tial­ly Alzheimer’s.

The Con­necti­cut biotech an­nounced Wednes­day that it in-li­censed an oral, brain-pen­e­trant dual in­hibitor of TYK2 and JAK1 from Chi­nese biotech High­lightLL Phar­ma­ceu­ti­cal. The deal in­cludes $20 mil­lion up­front in a 50/50 split be­tween cash and Bio­haven eq­ui­ty. The of­fer in­cludes an ad­di­tion­al $950 mil­lion in de­vel­op­ment and com­mer­cial mile­stones, plus roy­al­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER